Retrospective analysis of HLA mismatch burden and transplant outcomes after deceased-donor kidney transplantation in a setting without HLA-based allocation
This retrospective study of deceased-donor kidney transplants in Sri Lanka found that while higher HLA mismatch burden significantly increases the risk of acute rejection and reduces rejection-free survival, it does not independently predict graft or patient survival, which are primarily driven by infection and recipient factors such as age and diabetes.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
When a kidney fails, the body's waste filtration system collapses, leaving patients dependent on machines to clean their blood. For those who can receive a new kidney, the procedure offers a return to a life that dialysis cannot match. However, the human immune system is designed to attack anything it does not recognize as its own. When a new organ arrives, the body often mistakes it for an invader and launches an attack. To prevent this, doctors look for a match between the donor and the recipient, checking for specific markers on the surface of cells called human leukocyte antigens. The fewer differences there are between these markers, the less likely the immune system is to reject the new organ. In many parts of the world, this matching process is a central part of deciding who gets a kidney from a deceased donor. But in Sri Lanka, where the supply of donor kidneys is limited and allocation follows different rules, doctors do not use these markers to decide who receives an organ. Instead, they rely on blood type compatibility and a quick test to ensure the recipient does not already have antibodies against the donor. This leaves a critical question unanswered: in a system where matching is ignored, does the degree of difference between donor and recipient still matter for the patient's long-term health?
Researchers at the National Hospital of Sri Lanka set out to answer this by looking back at the records of 87 adults who received a kidney from a deceased donor between 2017 and 2024. They gathered the complete genetic data for both the donors and the recipients to count exactly how many of these immune markers were different. They then tracked what happened to these patients over a median period of just over three and a half years. The team was looking for a connection between the number of mismatches and three specific outcomes: whether the body rejected the kidney, whether the patient survived, and whether the kidney itself continued to function.
The study revealed a clear and direct link between the number of mismatches and the risk of rejection. As the number of differences between the donor and recipient increased, the likelihood of the immune system attacking the new kidney rose steadily. Among the patients with the fewest differences, rejection was rare. In contrast, every single patient with the maximum number of differences experienced an episode of rejection. When the researchers grouped the patients into those with low mismatch and those with high mismatch, they found that the high mismatch group was far more likely to suffer from acute rejection. This association held true even after accounting for other factors, such as how long the kidney was without blood flow before being transplanted. The data showed that delayed function of the kidney immediately after surgery also made rejection more likely, but the genetic mismatch remained a powerful independent predictor of trouble.
However, the story changed when the researchers looked at whether the patients lived or died, or whether the kidney eventually failed completely. Despite the higher rate of rejection in the mismatched group, the degree of genetic difference did not independently predict who would lose their kidney or who would pass away. In this specific group of patients, the most significant factors determining survival were the age of the recipient and whether they had diabetes. Patients aged 60 or older, and those whose kidney failure was caused by diabetes, faced a much higher risk of death. The leading cause of death was infection, which accounted for nearly all fatalities. Because the immune system is suppressed to prevent rejection, these older and diabetic patients were more vulnerable to infections like pneumonia, a risk that had nothing to do with how well their donor and recipient genes matched.
The findings suggest that while ignoring genetic matching in the allocation process does not stop the immune system from reacting, it does not necessarily shorten the life of the patient in this specific setting. The genetic mismatch acts as a trigger for the immune system to attack the organ, leading to rejection episodes that can be treated, but the ultimate fate of the patient is driven by their own health conditions and their susceptibility to infection. The researchers concluded that while using genetic matching data could help reduce the frequency of rejection and the need for stronger immunosuppression drugs, the most effective way to improve survival rates in this population would be to focus on preventing infections, particularly among older patients and those with diabetes. This study provides the first evidence from Sri Lanka that even without a matching system, the genetic distance between donor and recipient is a real and measurable force in the immediate battle against rejection, even if it is not the deciding factor in long-term survival.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.